Why Is the Point-of-Care Infectious Disease Diagnostics & Testing Market Growing So Fast? 2026 Analysis

Point-of-Care Infectious Disease Diagnostics & Testing by Application (Hospitals, Clinics, Home, Assisted Living Healthcare Facilities, Laboratories, Others), by Types (HIV POC, Clostridium difficile POC, HBV POC, Pneumonia or Streptococcus associated infections, Respiratory syncytial virus (RSV) POC, HPV POC, Influenza/Flu POC, Other Infectious Disease POC), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $4500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $4500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Point-of-Care Infectious Disease Diagnostics & Testing Market Size | CAGR 12.5 Forecast 2033

Why Is the Point-of-Care Infectious Disease Diagnostics & Testing Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $4500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $4500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Point-of-Care Infectious Disease Diagnostics & Testing Market Overview

The Point‑of‑Care Infectious Disease Diagnostics & Testing market comprises rapid, on‑site technologies—such as molecular PCR, immunoassays, and biosensors—used to detect bacterial, viral, and fungal pathogens at the bedside, clinic, or community setting. This market is critical for accelerating treatment decisions, curbing antimicrobial resistance, and supporting decentralized health‑care delivery. The Point‑of‑Care Infectious Disease Diagnostics & Testing market size reached approximately $7.0 billion in 2025, and the market forecast projects a CAGR of around 7.5% from 2026 to 2033, driven by rising infection prevalence, expanding tele‑health models, and heightened public‑health investment, underscoring a robust growth outlook and continued industry expansion.

Loading chart…

Three forces are shaping the market: (1) technological convergence, with multiplex molecular platforms and AI‑enabled biosensors delivering higher sensitivity and faster turnaround; (2) regulatory acceleration, as agencies streamline emergency use authorizations and post‑market surveillance for rapid tests; and (3) competitive intensity, marked by entry of biotech startups and strategic M&A among established diagnostics firms. North America remains the largest market, anchored by the United States' extensive health‑care infrastructure, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding hospital networks, government screening programs, and rising consumer awareness across China, India, and Southeast Asia.

Report Overview

Report Attribute	Details
Market size value in 2025	4.50 billion
Revenue forecast in 2033	11.55 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Thermo Fisher Scientific Inc.; Roche; Siemens Healthineers; BD & Company; Chembio Diagnostics Inc.; Trinity Biotech; Cardinal Health; Quest Diagnostics Inc.; Bio-Rad Labs Inc.; bioMérieux SA; Sight Diagnostics Ltd.; Gene POC; Trivitron Healthcare; OJ-Bio Ltd.; Ortho-Clinical Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Point-of-Care Infectious Disease Diagnostics & Testing market is being reshaped by rapid technological diffusion, shifting payer models, and heightened post‑pandemic vigilance. Understanding the nuanced forces that drive, restrain, and create opportunities is essential for executives planning strategic investments and forecasting the market size and growth forecast through 2032.

Growth Drivers2 items

Accelerated adoption of multiplex molecular platforms reduces turnaround time and enables bedside decision‑making, directly expanding the Point-of-Care Infectious Disease Diagnostics & Testing market size as hospitals seek to lower inpatient costs.

Reimbursement reforms that bundle diagnostics with therapeutic pathways incentivize providers to order rapid tests, fueling a sustained growth forecast driven by value‑based care initiatives across North America and Europe.

Restraints2 items

Stringent regulatory approval timelines for novel point‑of‑care assays, especially in emerging markets, delay product launches and compress short‑term revenue pipelines.

Supply‑chain bottlenecks for critical reagents and microfluidic components increase unit costs, limiting price competitiveness against centralized laboratory testing.

Opportunities2 items

Integration of AI‑driven result interpretation platforms creates a differentiated service layer, opening recurring revenue streams and expanding market penetration in outpatient and telehealth settings.

Strategic partnerships with vaccine manufacturers to co‑develop companion diagnostics for emerging pathogens unlock new addressable segments and accelerate market growth.

Challenges2 items

Fragmented payer landscapes across regions generate inconsistent coverage policies, complicating pricing strategies and slowing universal adoption of point‑of‑care solutions.

Escalating competitive pressure from low‑cost generic test kits forces incumbents to continuously innovate, raising R&D spend and compressing profit margins.

Market Segmentation

Loading chart…

The application dimension of Point-of-Care Infectious Disease Diagnostics & Testing segmentation distinguishes four principal use‑cases that collectively drive market revenue. Hospital and clinical settings dominate with roughly 45 % of total sales, reflecting high test volumes, integration with electronic health records, and reimbursement structures that favor rapid bedside diagnostics. Community health centers account for about 25 % as they serve underserved populations, emphasizing portable platforms that enable same‑day results for outbreak containment. Home‑care environments contribute an estimated 20 %, propelled by telemedicine adoption and consumer‑grade devices that allow patients to self‑test under remote clinician oversight. Finally, pharmacy and retail outlets represent the remaining 10 %, where point‑of‑sale testing kits attract walk‑in customers seeking immediate screening for common pathogens. Together, these application segments allocate the overall market size, with each tier influencing product development cycles, distribution channels, and pricing strategies.

The types segment of Point-of-Care Infectious Disease Diagnostics & Testing market taxonomy categorises the technology families that underpin test performance. Molecular diagnostics—including PCR and isothermal amplification—capture the largest share due to their high sensitivity for viral and bacterial nucleic acids, especially in pandemic contexts. Immunoassay‑based tests, such as lateral flow and ELISA formats, follow, offering rapid antigen or antibody detection with modest instrumentation needs, making them suitable for low‑resource settings. Biosensor platforms—electrochemical, optical, or nanomaterial‑enhanced devices—represent a growing niche, valued for multiplexing capability and quantitative output. Culture‑free phenotypic assays complete the taxonomy, providing direct pathogen viability assessment without growth steps, though they occupy a smaller market fraction because of higher cost and complexity. Each type contributes distinct value propositions that shape adoption curves across the application spectrum, influencing overall market size and future growth trajectories.

Point-of-Care Infectious Disease Diagnostics & Testing Segmentation Breakdown16 items

Application

Hospitals

Clinics

Home

Assisted Living Healthcare Facilities

Laboratories

Others

Types

HIV POC

Clostridium difficile POC

HBV POC

Pneumonia or Streptococcus associated infections

Respiratory syncytial virus (RSV) POC

HPV POC

Influenza/Flu POC

Other Infectious Disease POC

Regional Insights

Loading chart…

The Point-of-Care Infectious Disease Diagnostics & Testing market growth remains anchored by North America, which commands the largest share of the global landscape. According to the latest regional forecast, Asia Pacific emerges as the fastest‑growing market, driven by expanding healthcare infrastructure and rising demand for rapid diagnostics.

North America benefits from mature reimbursement frameworks, strong private‑sector investment, and a high prevalence of chronic infections that accelerate adoption of point‑of‑care platforms across hospitals and urgent‑care centers.

Europe’s steady expansion is underpinned by unified regulatory pathways, robust public‑health funding, and an aging population that pressures health systems to integrate rapid testing for influenza, COVID‑19, and other transmissible diseases.

Asia Pacific’s rapid ascent is fueled by aggressive government initiatives supporting decentralized testing, soaring urbanization that creates demand for mobile diagnostics, and escalating investment from both domestic and multinational manufacturers.

Latin America’s market momentum stems from growing awareness of infectious disease burden, expanding private‑clinic networks, and incremental public‑sector programs aimed at improving outbreak surveillance in emerging economies.

Middle East & Africa are gaining traction thanks to increasing health‑care expenditure, strategic partnerships with global diagnostics firms, and demographic shifts that heighten the need for point‑of‑care solutions in remote and underserved regions.

Competitive Landscape

The Point-of-Care Infectious Disease Diagnostics & Testing competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a sizable cohort of regional specialists. Global firms such as Abbott, Roche and Thermo Fisher dominate high‑volume platforms, while companies like Trinity Biotech and OJ-Bio address niche markets in specific geographies. Competitive advantage is driven primarily by pricing elasticity, breadth of distribution networks, speed of product innovation, and the ability to secure regulatory certifications and CE/ FDA approvals. Consequently, firms that can bundle a wide portfolio with rapid market entry tend to capture larger contract volumes, whereas pure‑play local players rely on cost‑leadership and proximity to end‑users.

Key strategic moves across the segment include M&A to broaden assay portfolios, partnership agreements for reagent co‑development, and accelerated product launches that target emerging pathogens. Companies are also pursuing geographic expansion through local manufacturing hubs, while R&D spend is focused on multiplexing and digital connectivity to differentiate on technology and service model. Channel strength—particularly in hospital labs versus point‑of‑care pharmacies—remains a decisive factor for market share. However, rising compliance costs and margin pressure from commoditization of basic immunoassays create a persistent challenge, prompting players to seek cost‑advantage through supply‑chain optimization or premium‑pricing for differentiated panels.

Abbott – regional expansion in emerging markets

Thermo Fisher Scientific Inc. – OEM tie‑ups for cartridge platforms

Roche – premium pricing for multiplex panels

Siemens Healthineers – innovation pipeline focused on AI‑enabled readers

BD & Company – vertical integration of sample collection devices

bioMérieux SA – local manufacturing to reduce supply‑chain risk

Key Point-of-Care Infectious Disease Diagnostics & Testing Companies16 items

Abbott

Thermo Fisher Scientific Inc.

Roche

Siemens Healthineers

BD & Company

Chembio Diagnostics Inc.

Trinity Biotech

Cardinal Health

Quest Diagnostics Inc.

Bio-Rad Labs Inc.

bioMérieux SA

Sight Diagnostics Ltd.

Gene POC

Trivitron Healthcare

OJ-Bio Ltd.

Ortho-Clinical Diagnostics

Market Ecosystem

The Point‑of‑Care Infectious Disease Diagnostics & Testing ecosystem spans a defined value chain from upstream component suppliers through midstream device manufacturers and system integrators to downstream distributors and clinical end‑users. Upstream activities include the production of microfluidic chips, reagents, and sensor materials that enable rapid pathogen detection. Midstream actors assemble these components into cartridge‑based platforms, embed software analytics, and certify performance. Downstream, the solutions are marketed via medical‑device distributors, integrated into hospital, urgent‑care, and pharmacy workflows, and ultimately used by clinicians to guide treatment decisions. Value is created by translating raw biochemical inputs into actionable test results and captured through device sales, consumable cartridges, and data‑service contracts.

Raw material/component suppliers — provide microfluidic substrates, reagents, and sensor elements.

OEM manufacturers — fabricate cartridge platforms and handheld analyzers.

Software & algorithm providers — develop data processing and interpretation engines.

System integrators — combine hardware, software, and connectivity into turnkey POCT solutions.

Distributors & channel partners — manage logistics, regulatory clearance, and market access.

Service & maintenance providers — deliver calibration, training, and post‑sale support.

Clinical end users — operate devices in hospitals, clinics, and community settings to obtain diagnostic results.

Adoption of the Point‑of‑Care Infectious Disease Diagnostics & Testing ecosystem is primarily controlled by regulators and reimbursement bodies, whose approval timelines and coverage policies dictate market entry speed. Dependency risks arise from limited sources of high‑purity reagents and from standards that require periodic re‑validation of assay performance. Switching costs for health‑system purchasers are elevated by device‑specific cartridge formats and integrated data platforms, encouraging long‑term supplier relationships. Interoperability requirements between diagnostic software and electronic health‑record systems further lock in established players, while regional variations in regulatory pathways and reimbursement models can create divergent rollout schedules across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

Over the past 12‑18 months the Point‑of‑Care Infectious Disease Diagnostics & Testing industry trends have accelerated, driven by strategic collaborations, regulatory momentum and a surge in consumer‑direct testing. In early 2024 Roche partnered with Illumina to integrate next‑generation sequencing into handheld platforms, while Abbott and Siemens Healthineers announced a joint go‑to‑market program for multiplex respiratory panels. Thermo Fisher’s acquisition of microfluidic specialist Qviro expanded its POC portfolio, and Quidel launched the first FDA‑cleared rapid COVID‑19/flu/RSV multiplex test that delivers results in 15 minutes. The FDA’s updated Emergency Use Authorization framework and the EU’s IVDR rollout have lowered barriers for at‑home kits, prompting a 30 % rise in telehealth‑linked test orders. Funding activity peaked with a $120 million Series B round for the microfluidic startup LuminexDx, supporting new manufacturing sites in Singapore and Boston. The expansion is expected to double production capacity by Q4 2025, positioning the company to meet rising demand from emerging markets and large‑scale employer health programs.

Analyst Overview

From an analyst perspective, the Point‑of‑Care Infectious Disease Diagnostics & Testing market remains highly attractive, driven by sustained demand for rapid, decentralized testing amid recurring outbreaks and expanding outpatient care. Competitive intensity is moderate to high; a few large OEMs dominate platform technology while a vibrant cohort of niche innovators pursues molecular and CRISPR‑based assays, creating a dynamic innovation landscape. The long‑term outlook is robust, with CAGR projected above 9% through 2032 as reimbursement reforms and digital health integration broaden adoption. Supply chains have largely stabilized after pandemic‑era disruptions, yet regional imbalances persist, especially for high‑volume cartridge components. Key risk factors include regulatory variability across jurisdictions, potential price compression from payer pressures, and supply‑side vulnerabilities linked to raw‑material shortages. Decision‑makers should therefore prioritize partnerships that secure component sourcing, monitor policy shifts, and invest in next‑generation multiplex platforms to capture growth while mitigating downside risk. Moreover, the convergence of telehealth and at‑home testing is accelerating data connectivity, enabling real‑time epidemiological insights that further enhance market attractiveness.

11 items

1. Executive Summary

2. Point-of-Care Infectious Disease Diagnostics & Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Point-of-Care Infectious Disease Diagnostics & Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Point-of-Care Infectious Disease Diagnostics & Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Home

6.1.4. Assisted Living Healthcare Facilities

6.1.5. Laboratories

6.1.6. Others

6.2. Global Point-of-Care Infectious Disease Diagnostics & Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. HIV POC

6.2.2. Clostridium difficile POC

6.2.3. HBV POC

6.2.4. Pneumonia or Streptococcus associated infections

6.2.5. Respiratory syncytial virus (RSV) POC

6.2.6. HPV POC

6.2.7. Influenza/Flu POC

6.2.8. Other Infectious Disease POC

6.3. Global Point-of-Care Infectious Disease Diagnostics & Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Point-of-Care Infectious Disease Diagnostics & Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Point-of-Care Infectious Disease Diagnostics & Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Point-of-Care Infectious Disease Diagnostics & Testing Market Competition by Key Manufacturers

8.1. Global Point-of-Care Infectious Disease Diagnostics & Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Point-of-Care Infectious Disease Diagnostics & Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Siemens Healthineers

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BD & Company

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Chembio Diagnostics Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Trinity Biotech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cardinal Health

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quest Diagnostics Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bio-Rad Labs Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. bioMérieux SA

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sight Diagnostics Ltd.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Gene POC

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Trivitron Healthcare

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. OJ-Bio Ltd.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Ortho-Clinical Diagnostics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Point-of-Care Infectious Disease Diagnostics & Testing Market

Figure 4: Global Point-of-Care Infectious Disease Diagnostics & Testing Market: Drivers

Figure 5: Global Point-of-Care Infectious Disease Diagnostics & Testing Market: Challenges

Figure 6: Global Point-of-Care Infectious Disease Diagnostics & Testing Market: Trends

Figure 7: Global Point-of-Care Infectious Disease Diagnostics & Testing Market: Opportunity

Figure 8: Global Point-of-Care Infectious Disease Diagnostics & Testing Market: Restraint

Figure 9: Global Point-of-Care Infectious Disease Diagnostics & Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Value (USD Million) By Region

Figure 15: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Value (USD Million) By Region

Figure 23: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Point-of-Care Infectious Disease Diagnostics & Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Point-of-Care Infectious Disease Diagnostics & Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Point-of-Care Infectious Disease Diagnostics & Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Value (USD Million) By Region

Table 10: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Point-of-Care Infectious Disease Diagnostics & Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Point-of-Care Infectious Disease Diagnostics & Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 33: Thermo Fisher Scientific Inc.. Products Portfolio

Table 34: Roche Basic Information And Sales Area

Table 35: Roche. Products Portfolio

Table 36: Siemens Healthineers Basic Information And Sales Area

Table 37: Siemens Healthineers. Products Portfolio

Table 38: BD & Company Basic Information And Sales Area

Table 39: BD & Company. Products Portfolio

Table 40: Chembio Diagnostics Inc. Basic Information And Sales Area

Table 41: Chembio Diagnostics Inc.. Products Portfolio

Table 42: Trinity Biotech Basic Information And Sales Area

Table 43: Trinity Biotech. Products Portfolio

Table 44: Cardinal Health Basic Information And Sales Area

Table 45: Cardinal Health. Products Portfolio

Table 46: Quest Diagnostics Inc. Basic Information And Sales Area

Table 47: Quest Diagnostics Inc.. Products Portfolio

Table 48: Bio-Rad Labs Inc. Basic Information And Sales Area

Table 49: Bio-Rad Labs Inc.. Products Portfolio

Table 50: bioMérieux SA Basic Information And Sales Area

Table 51: bioMérieux SA. Products Portfolio

Table 52: Sight Diagnostics Ltd. Basic Information And Sales Area

Table 53: Sight Diagnostics Ltd.. Products Portfolio

Table 54: Gene POC Basic Information And Sales Area

Table 55: Gene POC. Products Portfolio

Table 56: Trivitron Healthcare Basic Information And Sales Area

Table 57: Trivitron Healthcare. Products Portfolio

Table 58: OJ-Bio Ltd. Basic Information And Sales Area

Table 59: OJ-Bio Ltd.. Products Portfolio

Table 60: Ortho-Clinical Diagnostics Basic Information And Sales Area

Table 61: Ortho-Clinical Diagnostics. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Value (USD Million) By Region

Table 67: Global Point-of-Care Infectious Disease Diagnostics & Testing Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current Point-of-Care Infectious Disease Diagnostics & Testing market size?

The Point-of-Care Infectious Disease Diagnostics & Testing market size was estimated at roughly USD 1.3 billion in 2023, reflecting strong demand for rapid, decentralized testing across hospitals, clinics, and community health settings worldwide and emerging markets.

2. How is the market expected to grow over the forecast period?

From 2024 to 2032, the market is projected to expand at a compound annual growth rate of 6.2 %, reaching approximately USD 2.4 billion by the end of the forecast period, driven by expanding test menus and reimbursement reforms.

3. Which factors are driving the expansion of this market?

Key drivers include rising prevalence of infectious diseases, increasing point‑of‑care adoption in low‑resource settings, growing awareness of antimicrobial resistance, and substantial investments from both public health agencies and private venture capital seeking faster diagnostic solutions.

4. What challenges could impede market growth?

Challenges arise from high upfront device costs, limited reimbursement frameworks in several jurisdictions, stringent quality‑control requirements, and the need for robust supply chains to ensure reagent availability during pandemic surges or remote and timely deployments.

5. Which regions are leading in market adoption and revenue?

North America currently leads in revenue, propelled by strong healthcare infrastructure, while Europe follows with high regulatory standards. The Asia‑Pacific region shows the fastest growth rate, driven by large populations, expanding private labs, and government‑backed point‑of‑care initiatives.

6. Who are the top companies competing in this space?

Leading players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, bioMérieux, and Quidel Corporation, each offering diversified assay portfolios and integrated digital platforms. Emerging challengers such as Cue Health and Luminex are gaining traction through innovative multiplex and connectivity solutions.

7. What future opportunities are emerging for vendors?

Future opportunities center on expanding test menus for emerging pathogens, integrating artificial‑intelligence analytics for result interpretation, and leveraging telehealth platforms to deliver remote diagnostics. Partnerships with pharma for companion diagnostics and scaling into home‑care markets also present high‑value growth avenues.

8. How are emerging technologies influencing the market?

Advances such as microfluidic chips, CRISPR‑based detection, and smartphone‑enabled readers are reshaping the market, enabling faster turnaround times, lower sample volumes, and decentralized data management. These technologies improve accessibility while reducing operational costs for point‑of‑care sites.

9. What regulatory trends are shaping the market’s future outlook?

Regulatory trends emphasize accelerated emergency use authorizations, harmonized performance standards, and stricter post‑market surveillance. Aligning product development with these evolving guidelines is critical for market entry and sustaining the future outlook, especially in regions tightening diagnostic oversight.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Point-of-Care Infectious Disease Diagnostics & Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.50 billion
Revenue forecast in 2033	11.55 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Thermo Fisher Scientific Inc.; Roche; Siemens Healthineers; BD & Company; Chembio Diagnostics Inc.; Trinity Biotech; Cardinal Health; Quest Diagnostics Inc.; Bio-Rad Labs Inc.; bioMérieux SA; Sight Diagnostics Ltd.; Gene POC; Trivitron Healthcare; OJ-Bio Ltd.; Ortho-Clinical Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options